Probiotics have been evaluated as therapeutic agents for cancer treatment in an increasing number of studies. This study investigated the inhibitory and cytotoxic effects of specific Lactobacillus strains on a human colorectal adenocarcinoma cell line (HT-29). The strains assessed were Limosilactobacillus (L.) reuteri VA 102, Ligilactobacillus (L.) animalis VA 105, and Limosilactobacillus (L.) reuteri KCTC 3594 (ATCC 23272). The viability of HT-29 cells was evaluated using the MTT assay. The findings revealed that cell-free supernatants (CFS) exhibited significant anticancer effects. Heat-inactivated L. reuteri VA 105 and L. reuteri KCTC 3594 induced a pronounced reduction in cell viability. Furthermore, live cultures of L. reuteri VA 105 and L. reuteri VA 102 also showed reduced cell viability compared to the control group. These results suggest that CFS and heat-inactivated cells may be more suitable for therapeutic applications than live bacteria owing to their improved safety profiles and reduced potential for adverse effects. Our findings also emphasize the potential anticancer benefits of these LAB strains.

Abstract
INTRODUCTION
MATERIALS AND METHODS
    Bacteria strains, growth conditions
    Cell culture condition
    Cell viability assay
    Preparation Lactobacillus strain live, heat-killed, andcell-free supernatant
    Statistical analysis
RESULTS
    CFS of Lactobacillus strains inhibit the growth ofCT-29 cells in a dose- and strain-dependent manner
    Live Lactobacillus strain HT-29 cells viability
    Effect inactivated Lactobacillus strain HT-29 cell viability
DISCUSSION
ACKNOWLEDGEMENTS
REFERENCES

• Said Abdi Salad(Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University, Jinju 52828, Korea)
• Tran Xuan Ngoc Huy(Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University, Jinju 52828, Korea)
• Trang Thi Nguyen(Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University, Jinju 52828, Korea)
• Ched Nicole Turbela Aguilar(Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University, Jinju 52828, Korea)
• Suk Kim(Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University, Jinju 52828, Korea) Corresponding author
• Chaerim Park(V1bio Inc., B-1605, 167, Songpa-daero, Sonpa-gu, Seoul 05855, Korea)
• Hee Chol Kang(V1bio Inc., B-1605, 167, Songpa-daero, Sonpa-gu, Seoul 05855, Korea)
• Il-Hwan Kim(V1bio Inc., B-1605, 167, Songpa-daero, Sonpa-gu, Seoul 05855, Korea)